Oxycodone/naloxone versus placebo for acute spinal pain in compliant participants: secondary analysis of a randomised clinical trial
Primary result · Pain severityResult — go to the resultMean difference 0.78 95% CI 0.22–1.33Authors' conclusion
This secondary analysis of a randomised controlled trial highlights the non-effectiveness of an oxycodone/naloxone combination in acute spinal pain compared with placebo, even when the population complies with the treatment regimen.
Study context
- Population
- Participants with acute back/neck pain who complied with the regimen
- Comparison
- Oxycodone/naloxone vs placebo in compliant participants
- Primary endpoint
- Pain severity
- Follow-up
- Week 6
Methodological detailsprespecified complier average causal effect analysis, propensity-weighting, joint modelling, propensity-matching, per-protocol analysis
- Prespecified complier average causal effect analysis
- Propensity-weighting
- Joint modelling
- Propensity-matching
- Per-protocol analysis
Primary result
As reported in the abstract
Mean difference
0.78
95% CI 0.22–1.33
P = 0.006
Oxycodone/naloxone vs Placebo
mean difference 0.78 (95% CI 0.22–1.33); P = 0.006
Secondary outcomes
Pain severity at weeks 2, 4, 12, 26 and 52; other approaches; compliance cut-off sensitivity analyses
- Either favoured the placebo group or showed no difference between groups
Original publication
Oxycodone/naloxone versus placebo for acute spinal pain in compliant participants: secondary analysis of a randomised clinical trial. Br J Anaesth. Published 20 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →